LAYN Serves as a Prognostic Biomarker and Downregulates Tumor-Infiltrating CD8⁺ T Cell Function in Hepatocellular Carcinoma

References

• Llovet JM. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Bray F. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Mortality, G. B. D. & Causes of Death, C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. doi:10.1016/S0140-6736(14)61682-2
   PubMed Web of Science ®Google Scholar
• Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis. 2022;54:154–163. doi:10.1016/j.dld.2021.06.023
   PubMedGoogle Scholar
• Tan DJH. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23:521–530. doi:10.1016/S1470-2045(22)00078-X
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–1763. doi:10.1053/j.gastro.2008.02.090
   PubMed Web of Science ®Google Scholar
• Zheng C. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017;169:1342–1356 e1316. doi:10.1016/j.cell.2017.05.035
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Simoni Y. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557:575–579. doi:10.1038/s41586-018-0130-2
   PubMed Web of Science ®Google Scholar
• Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209–223. doi:10.1038/s41577-021-00574-3
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509–8521. doi:10.1002/jcp.27782
   PubMed Web of Science ®Google Scholar
• Khan O. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571:211–218. doi:10.1038/s41586-019-1325-x
   PubMed Web of Science ®Google Scholar
• Blackburn SD. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29–37. doi:10.1038/ni.1679
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175:998–1013 e1020. doi:10.1016/j.cell.2018.10.038
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–499. doi:10.1038/nri3862
   PubMed Web of Science ®Google Scholar
• Zhou G. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153:1107–1119 e1110. doi:10.1053/j.gastro.2017.06.017
   PubMed Web of Science ®Google Scholar
• Li H. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56:1342–1351. doi:10.1002/hep.25777
   PubMed Web of Science ®Google Scholar
• Kuang DM. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327–1337. doi:10.1084/jem.20082173
   PubMed Web of Science ®Google Scholar
• Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res. 2009;69:8067–8075.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhuo W, Wang Y, Ao X, An J. Down-regulation of layilin, a novel hyaluronan receptor, via RNA interference, inhibits invasion and lymphatic metastasis of human lung A549 cells. Biotechnol Appl Biochem. 2008;50:89–96. doi:10.1042/BA20070138
   PubMed Web of Science ®Google Scholar
• Kaji T. Layilin enhances the invasive ability of malignant glioma cells via SNAI1 signaling. Brain Res. 2019;1719:140–147. doi:10.1016/j.brainres.2019.05.034
   PubMed Web of Science ®Google Scholar
• Pan JH. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol. 2019;10:6. doi:10.3389/fimmu.2019.00006
   PubMed Web of Science ®Google Scholar
• Yang Y. Targeting LAYN inhibits colorectal cancer metastasis and tumor-associated macrophage infiltration induced by hyaluronan oligosaccharides. Matrix Biol. 2023;117:15–30. doi:10.1016/j.matbio.2023.02.005
   PubMed Web of Science ®Google Scholar
• Mahuron KM. Layilin augments integrin activation to promote antitumor immunity. J Exp Med. 2020;217. doi:10.1084/jem.20192080
   PubMed Web of Science ®Google Scholar
• Brummelman J. High-dimensional single cell analysis identifies stem-like cytotoxic CD8(+) T cells infiltrating human tumors. J Exp Med. 2018;215:2520–2535. doi:10.1084/jem.20180684
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004. doi:10.1016/j.immuni.2016.05.001
   PubMed Web of Science ®Google Scholar
• Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561. doi:10.1080/2162402X.2016.1249561
   PubMed Web of Science ®Google Scholar
• Wang JJ. PD-L1, PD-1, LAG-3, and TIM-3 in melanoma: expression in brain metastases compared to corresponding extracranial tumors. Cureus. 2019;11:e6352. doi:10.7759/cureus.6352
   PubMed Web of Science ®Google Scholar
• Wang Z. CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduct Target Ther. 2020;5:148. doi:10.1038/s41392-020-00259-8
   PubMed Web of Science ®Google Scholar
• Harjunpaa H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078. doi:10.3389/fimmu.2019.01078
   PubMed Web of Science ®Google Scholar
• Eberhardt CS. Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer. Nature. 2021;597:279–284. doi:10.1038/s41586-021-03862-z
   PubMed Web of Science ®Google Scholar
• Ma J. PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7:331. doi:10.1186/s40425-019-0814-7
   PubMed Web of Science ®Google Scholar
• Reiser J, Banerjee A. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res. 2016;2016:8941260. doi:10.1155/2016/8941260
   PubMed Web of Science ®Google Scholar
• Cao L, Zhu L, Cheng L. ncRNA-regulated LAYN Serves as a prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma: a bioinformatics analysis. Biomed Res Int. 2022;2022:5357114. doi:10.1155/2022/5357114
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN. Neoadjuvant PD-1 blockade in resectable lung cancer; nivolumab and ipilimumab in advanced melanoma; overall survival with combined nivolumab and ipilimumab in advanced melanoma; prolonged survival in stage III melanoma with ipilimumab adjuvant therapy; combined nivolumab and ipilimumab or monotherapy in untreated melanoma; nivolumab and ipilimumab versus ipilimumab in untreated melanoma; rapid eradication of a bulky melanoma mass with one dose of immunotherapy; genetic basis for clinical response to CTLA-4 blockade; genetic basis for clinical response to CTLA-4 blockade in melanoma; nivolumab plus ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in melanoma; hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2018;379:2185. doi:10.1056/NEJMx180040
   PubMedGoogle Scholar
• Motzer RJ. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–1290. doi:10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. doi:10.1186/s13045-023-01499-1
   PubMed Web of Science ®Google Scholar
• Liu JTargeting PD-1 and tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines. J Immunother. 2016;39:171–180. doi:10.1097/CJI.0000000000000122
   PubMed Web of Science ®Google Scholar
• Di Pilato M. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184:4512–4530 e4522. doi:10.1016/j.cell.2021.07.015
   PubMed Web of Science ®Google Scholar